Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic,...

Area of Science:

• Bone biology
• Pharmacology
• Biomedical engineering

Background:

• Bone loss due to immobilization is a significant clinical challenge.
• Antiresorptive drugs are a potential therapeutic strategy, but their efficacy requires further elucidation.
• Understanding drug effects on bone remodeling is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the effects of tiludronate on bone loss induced by immobilization in a rat model.
• To evaluate tiludronate's impact on bone microarchitecture and cellular activity at different time points.
• To determine the optimal dosage and timing for tiludronate's preventive effects.

Main Methods:

• Utilized a tail-suspension rat model to simulate immobilization-induced bone loss.
• Employed three-dimensional microtomography, dual X-ray absorptiometry, and histomorphometry for bone analysis.
• Administered tiludronate (0.5 or 5 mg/kg) or vehicle subcutaneously every other day.

Main Results:

• Tiludronate prevented bone loss in the primary spongiosa by day 7.
• Bone loss in the secondary spongiosa, characterized by decreased trabecular thickness and number, was observed from day 13.
• High-dose tiludronate fully prevented an 80% decrease in bone mass by day 23, increasing trabecular number without preventing thinning.

Conclusions:

• Tiludronate demonstrates preventive effects against immobilization-induced bone loss in rats.
• The drug's efficacy appears linked to alterations in bone modeling, increasing trabecular number in both primary and secondary spongiosa.
• Tiludronate's preventive action occurs despite reduced bone formation, suggesting complex mechanisms of action.